Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

Purpose: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. Methods: HER2 positive patients received oral metronomic capecitabin...

Full description

Bibliographic Details
Main Authors: Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Breast
Subjects:
Phase II study
Metastatic breast cancer
HER2-Positive
pyrotinib
capecitabine
metronomic chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762300557X

Internet

http://www.sciencedirect.com/science/article/pii/S096097762300557X

Similar Items